Efficacy and Safety of Rivaroxaban Plus Aspirin in Wom Coronary or Peripheral Artery Disease

Cardiovascular Research

117, 942-949

DOI: 10.1093/cvr/cvaa100

Citation Report

#	Article	IF	Citations
1	Rivaroxaban: A Review for Secondary CV Prevention in CAD and PAD. Drugs, 2020, 80, 1465-1475.	15.5	13
2	Review on Characteristics and Analytical Methods of Rivaroxaban. Critical Reviews in Analytical Chemistry, 2022, 52, 865-877.	7.9	24
3	Long-Term Dual Antithrombotic Therapy (DAT): Is It Efficient and Safe in Women?. Cardiovascular Research, 2021, 117, 653-654.	13.5	0
4	Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial. Journal of the American College of Cardiology, 2021, 77, 511-525.	12.0	17
5	Progress in Aorta and Peripheral Cardiovascular Disease Research. Cardiovascular Research, 2021, 117, 2045-2053.	13.5	7
6	Aspirin Dosing for Atherosclerotic Cardiovascular Disease: Should We Be More ADAPTABLE?. Cardiovascular Research, 2021, 117, e123-e125.	13.5	2
7	Direct Oral Anticoagulants Combined With Antiplatelet Therapy in the Treatment of Coronary Heart Disease: An Updated Meta-Analysis. Drugs, 2021, 81, 2003-2016.	15.5	7
8	Understanding the Role of nACE2 in Neurogenic Hypertension Among COVID-19 Patients. Hypertension Research, 2022, 45, 254-269.	4.7	13
9	Sex Differences in Peripheral Artery Disease. Circulation Research, 2022, 130, 496-511.	15.7	190
10	Sex-Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD. Journal of the American Heart Association, 2022, 11, e024655.	5.8	16
11	Endothelial Cell Dysfunction: Implications for the Pathogenesis of Peripheral Artery Disease. Frontiers in Cardiovascular Medicine, 2022, 9, 1054576.	3.2	51
12	Sex Differences in the Clinical Presentation and Management of Peripheral Artery Disease. Journal of Vascular Nursing, 2023, 41, 36-37.	1.0	1
13	A Hidden Problem: Peripheral Artery Disease in Women. European Heart Journal Quality of Care & Clinical Outcomes, 2023, 9, 342-350.	4.9	42
14	Sex and Racial Disparities in Peripheral Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2023, 43, 2099-2114.	7.9	26
15	A Systematic Review of Disparities in the Medical Management of Atherosclerotic Cardiovascular Disease in Females. Seminars in Vascular Surgery, 2023, 36, 517-530.	2.8	4
16	Impact of Frailty on the Benefits of Dual Pathway Inhibition for the Secondary Prevention of Cardiovascular Events in the COMPASS Randomised Trial. Canadian Journal of Cardiology, 2025, 0, 102-111.	3.8	7
17	Impact of Dual Antithrombotic Therapy With Aspirin and Rivaroxaban on Secondary Cardiovascular Outcomes. Medical Science Monitor, 2024, 30, e945457.	2.4	1
18	Rivaroxaban to Reduce the Risk of Major Cardiovascular Events in Patients With Chronic Coronary Artery Disease or Peripheral Artery Disease: A Narrative Review. Expert Opinion on Drug Safety, 2025, 24, 261-271.	3.2	7

#	Article	IF	Citations
19	Optimal Medical Treatment Versus Percutaneous Coronary Intervention in Chronic Coronary Syndrome. Indian Journal of Clinical Cardiology, 2025, 6, 105-113.	0.4	0
20	Comparative Efficacy and Safety of Anticoagulant Therapies in Coronary Artery Disease: A Network Meta-Analysis of Randomized Controlled Trials. BMC Cardiovascular Disorders, 2025, 25, 1-12.	3.3	2
21	Cardiovascular Disease: Sex and Gender Evidence for Cardiovascular Disease Prevention and Risk Factors for Ischemic Heart Disease, Heart Failure, Valvular Disease, Peripheral Arterial Disease; And Cardiovascular Disease in Pregnancy. , 2026, .		0
22	Épidémiologie descriptive & facteurs pronostiques de l'artériopathie oblitérante des membres inférieurs dans les populations négligées. , 0, .		0
23	Sex Differences in Peripheral Artery Disease. Physiology in Health and Disease, 2026, .	0.0	0
24	Peripheral Arterial Disease: Adverse Impacts, Disparities in Outcomes, and the Path Ahead. Lancet, The, 2026, 408, 1383-1396.	96.9	1